Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768310.793547377 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-207654 ◽

2015 ◽

Vol 75 (2) ◽

pp. 332-340 ◽

Cited By ~ 111

Author(s):

J T Merrill ◽

R F van Vollenhoven ◽

J P Buyon ◽

R A Furie ◽

W Stohl ◽

...

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

FRI0183 STUDY DESIGN FOR A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE MODERATE-DOSE CORTICOSTEROIDS

10.1136/annrheumdis-2019-eular.5707 ◽

2019 ◽

Author(s):

Anca Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Erin Connolly-Strong ◽

Richard Furie

Keyword(s):

Study Design ◽

Lupus Erythematosus ◽

Controlled Study ◽

Efficacy And Safety ◽

Moderate Dose ◽

Systemic Lupus ◽

Double Blind ◽

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Arthritis & Rheumatology ◽

10.1002/art.40049 ◽

2017 ◽

Vol 69 (5) ◽

pp. 1016-1027 ◽

Cited By ~ 98

Author(s):

William Stohl ◽

Andreas Schwarting ◽

Masato Okada ◽

Morton Scheinberg ◽

Andrea Doria ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2018-eular.1918 ◽

2018 ◽

Cited By ~ 1

Author(s):

D.J. Wallace ◽

R.A. Furie ◽

Y. Tanaka ◽

K.C. Kalunian ◽

M. Mosca ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Systemic Lupus ◽

Double Blind ◽

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-213032 ◽

2018 ◽

Vol 77 (6) ◽

pp. 883-889 ◽

Cited By ~ 33

Author(s):

Joan T Merrill ◽

William R Shanahan ◽

Morton Scheinberg ◽

Kenneth C Kalunian ◽

David Wofsy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Selective Inhibitor ◽

Phase Iii ◽

Systemic Lupus ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

B Cell Activating Factor

199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

10.1136/lupus-2019-lsm.199 ◽

2019 ◽

Cited By ~ 2

Author(s):

Maria E Silk ◽

Daniel J Wallace ◽

Richard A Furie ◽

Yoshiya Tanaka ◽

Kenneth C Kalunian ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Systemic Lupus ◽

Double Blind ◽

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41179 ◽

2020 ◽

Vol 72 (5) ◽

pp. 761-768 ◽

Cited By ~ 10

Author(s):

Ronald F. Vollenhoven ◽

Bevra H. Hahn ◽

George C. Tsokos ◽

Peter Lipsky ◽

Kaiyin Fei ◽

...

Keyword(s):

Phase Ii ◽

Lupus Erythematosus ◽

Crossover Trial ◽

Active Systemic Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

One Year